An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)

Trial Profile

An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; Registrational
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 12 Jan 2016 New trial record
    • 07 Jan 2016 The company expects to initiate a phase III program comprising two phase III efficacy trials and a long-term safety study in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top